Transl Lung Cancer Res: Safety and efficacy of nivolumab combined with recombinant human endostatin in the treatment of previously treated advanced non-small cell lung cancer

Evidence for the efficacy of immune checkpoint inhibitors (ICIs) in combination with antiangiogenic agents in previously treated patients with advanced non-small cell lung cancer (NSCLC) remains insufficient
.

Recently, a team from the Fifth Affiliated Hospital of Sun Yat-Sen University conducted a related study to evaluate the safety and efficacy of nivolumab (nivolumab) combined with recombinant human endostatin in previously treated advanced non-small cell lung cancer (NSCLC)

Evidence for the efficacy of immune checkpoint inhibitors (ICIs) in combination with antiangiogenic agents in previously treated patients with advanced non-small cell lung cancer (NSCLC) remains insufficient

The study included patients with EGFR/ALK-negative advanced NSCLC who progressed after previous therapy
.

Eligible patients received nivolumab (3 mg/kg, IV infusion, Day 1) every 2 weeks and recombinant human endostatin (210 mg, continuous IV infusion for 168 h) every 4 weeks until disease progression or discontinuation of treatment

The study included patients with EGFR/ALK-negative advanced NSCLC who progressed after previous therapy

Thirty-four patients were included, with a median age of 60 years (range 37-72 years), 26.

Thirty-four patients received a median of 4 cycles of treatment

Median follow-up was 12.
2 months (range, 2.
3-18.
1 months)
.

Median PFS (mPFS) was 6.

Median follow-up was 12.

Compared with patients with ECOG PS=2, patients with ECOG PS=0-1 had longer mPFS (12.
5 vs 1.
7 months; p<0.
001) and mOS (17.
1 months vs 3.
4 months; p<0.
001)
.

Likewise, patients with ≤ two metastases achieved longer mPFS (9.

Compared with patients with ECOG PS=2, patients with ECOG PS=0-1 had longer mPFS (12.

Eighteen (18/34, 52.
9%) patients had at least one treatment-related adverse event (TRAE), of which 4 (4/34, 11.
8%) had a grade 3 TRAE
.

Eighteen (18/34, 52.
9%) patients had at least one treatment-related adverse event (TRAE), of which 4 (4/34, 11.
8%) had a grade 3 TRAE
.

In conclusion, this study is the first to evaluate the effect of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
.

Given its favorable efficacy and safety profile, this combination is a promising treatment option
.

In conclusion, this study is the first to evaluate the effect of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
.
Given its favorable efficacy and safety profile, this combination is a promising treatment option
.
This study is the first to assess the effects of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
.
Given its favorable efficacy and safety profile, this combination is a promising treatment option
.
This study is the first to assess the effects of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
.
Given its favorable efficacy and safety profile, this combination is a promising treatment option
.

 

Original source:

Original source:

Lv W, Pei X, Zhao W, Cong Y, Wei Y, Li T, Zhang H, Lin Z, Saito Y, Kim JJ, Liang Z, Zhong B, Wang Z.
Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
Transl Lung Cancer Res.
2022 Feb;11(2):201-212.
doi: 10.
21037/tlcr-22-49.
PMID: 35280309; PMCID: PMC8902090.

Lv W, Pei X, Zhao W, Cong Y, Wei Y, Li T, Zhang H, Lin Z, Saito Y, Kim JJ, Liang Z, Zhong B, Wang Z.
Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
Transl Lung Cancer Res.
2022 Feb;11(2):201-212.
doi: 10.
21037/tlcr-22-49.
PMID: 35280309; PMCID: PMC8902090.

 

leave a message here